Literature DB >> 12828556

Retroviral transfer of T-cell receptor genes produces cells with a broad range of lytic activity.

R J Orentas1, L A Bircher, S Roskopf.   

Abstract

The ability to transfer the T-cell receptor (TCR) for antigen using a retroviral vector has opened the door to a new paradigm for T-cell-based immunotherapy. Using recombinant TCRs, a population of activated T cells can now be redirected to recognize and lyse cellular targets according to the specificity afforded by the transduced TCR genes. To examine the range of lytic activity displayed by the transduced TCRs, transduced T cells were re-cloned by limiting dilution and quantitatively analysed for lytic activity. The lytic activity of the transduced TCRs varied considerably, as determined by the Km and Vmax of lysis. The lytic activity seen in the secondary clones generated from vector-transduced peripheral blood mononuclear cell demonstrated that one of the clones approached the lytic activity of the parental 'TCR donor' cytotoxic T-cell lymphocyte (CTL) clone, whereas the remainder demonstrated either reduced Vmax or reduced Vmax and Km. Thus, the lytic activity of a transduced TCR depends not only on its genetic sequence but also on the cellular context within which it is expressed. Analysis of TCR Vbeta transcript levels by real time polymerase chain reaction revealed that while total Vbeta gene expression was fairly constant, expression of the retrovirally transduced Vbeta chain varied greatly in transduced CD8+ CTL clones.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828556      PMCID: PMC2980948          DOI: 10.1046/j.1365-3083.2003.01277.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  22 in total

1.  CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells.

Authors:  S P Lee; A T Chan; S T Cheung; W A Thomas; D CroomCarter; C W Dawson; C H Tsai; S F Leung; P J Johnson; D P Huang
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

2.  Kinetic analysis of cloned cytotoxic T lymphocyte reactivity against normal and leukaemic target cells.

Authors:  A V LeFever; R L Truitt
Journal:  J Immunogenet       Date:  1986 Apr-Jun

3.  Differential recognition and lysis of EL4 target cells by cytotoxic T cells: differences in H-2Kb antigenic density and cytoskeletal proteins.

Authors:  R V Flores; P J Gilmer
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

4.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.

Authors:  T M Clay; M C Custer; J Sachs; P Hwu; S A Rosenberg; M I Nishimura
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

5.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

Authors:  S A Rosenberg; P Aebersold; K Cornetta; A Kasid; R A Morgan; R Moen; E M Karson; M T Lotze; J C Yang; S L Topalian
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

6.  Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression.

Authors:  S R Riddell; M Rabin; A P Geballe; W J Britt; P D Greenberg
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

7.  Cytotoxic activity of human lymphocytes: quanitative analysis of T cell and K cell cytotoxicity, revealing enzyme-like kinetics.

Authors:  W P Zeijlemaker; R H van Oers; R E de Goede; P T Schellekens
Journal:  J Immunol       Date:  1977-10       Impact factor: 5.422

8.  Kinetic analysis of human IL-2 activated cytotoxic cells.

Authors:  A V LeFever; V D Piaskowski; J T Casper; R L Truitt
Journal:  Immunopharmacol Immunotoxicol       Date:  1991       Impact factor: 2.730

9.  T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Authors:  R M Blaese; K W Culver; A D Miller; C S Carter; T Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; S A Rosenberg; H Klein; M Berger; C A Mullen; W J Ramsey; L Muul; R A Morgan; W F Anderson
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

10.  Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.

Authors:  H E Heslop; C Y Ng; C Li; C A Smith; S K Loftin; R A Krance; M K Brenner; C M Rooney
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  5 in total

1.  Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma.

Authors:  Lisa A Jurgens; Rajiv Khanna; James Weber; Rimas J Orentas
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

Review 2.  Exploiting T cell receptor genes for cancer immunotherapy.

Authors:  S Xue; R Gillmore; A Downs; A Tsallios; A Holler; L Gao; V Wong; E Morris; H J Stauss
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

3.  A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.

Authors:  Emma C Morris; Aristotle Tsallios; Gavin M Bendle; Shao-An Xue; Hans J Stauss
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-20       Impact factor: 11.205

4.  Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer.

Authors:  Qingsong Yin; Xianfeng Zha; Lijian Yang; Shaohua Chen; Yubing Zhou; Xiuli Wu; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2011-01-11       Impact factor: 17.388

5.  Transduction of SIV-specific TCR genes into rhesus macaque CD8+ T cells conveys the ability to suppress SIV replication.

Authors:  Eugene V Barsov; Matthew T Trivett; Jacob T Minang; Haosi Sun; Claes Ohlen; David E Ott
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.